|Articles|July 1, 2011

Vetter dual-chamber technology

For complex compounds that require lyophilization, Vetter offers two efficient and user-friendly systems: the dual-chamber Vetter Lyo-Ject® syringe and dual-chamber V-LK® cartridge.

For complex compounds that require lyophilization, Vetter offers two efficient and user-friendly systems: the dual-chamber Vetter Lyo-Ject ® syringe and dual-chamber V-LK ® cartridge. Lyophilized drug resides in one chamber; diluent in the other. The drug is reconstituted just prior to administration in a few simple steps.

Competitive advantages

  • Product differentiation in a competitive arena, whether at initial launch or as part of a product lifecycle management strategy
  • Market opportunity in a growing homecare sector, as patients and caregivers seek drug-delivery systems easy and safe enough to use independently
  • Increased API yield, due to reduced overfill requirements

Dosage forms:
In addition to lyophilized-drug/diluent combinations, dual-chamber systems may also be used for liquid/liquid or powder/liquid drug combinations that require separation until point of use.

Sizes:


Dual-chamber syringe: in 1 ml, 2.5 ml and 5 ml sizes, covering fill volumes of 0.1 ml - 5 ml per chamber
Dual-chamber cartridge: in 1.5 ml size, covering fill volumes of 0.1 ml - 1.4 ml (first chamber) and 0.1 ml - 1.3 ml (second chamber)

Read more

For US inquiries please contact
+1-847-581-6888 or infoUS@vetter-pharma.com

For EU inquiries please contact
+49-751-3700-0 or info@vetter-pharma.com

Related to this article

Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
AAPS PharmSci 360: CMC Strategies, Part 3
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.